House and Home House and Home
Mon, January 11, 2010
Sun, January 10, 2010
Sat, January 9, 2010
Fri, January 8, 2010

CNS Response CEO George Carpenter to Present at the OneMedPlace Finance Forum


Published on 2010-01-08 07:00:20 - Market Wire
  Print publication without navigation


COSTA MESA, CA--(Marketwire - January 8, 2010) - CNS Response, Inc. (OTCBB: [ CNSO ]) today announced that its CEO, George Carpenter, will be presenting at the 2010 OneMedPlace Finance Forum taking place at the Sir Francis Drake Hotel in San Francisco, California. Mr. Carpenter is scheduled to speak on Tuesday, January 12, at 3:30 p.m. PST. The OneMedPlace Finance Forum connects emerging healthcare and life science companies with investors and strategic partners.

Mr. Carpenter will present a corporate overview and an update on the breakthrough results of the company's recent multi-site clinical study. In this study, the company's patented Referenced-EEG® system proved effective at predicting medication response for treatment-resistant patients approximately 65 percent of the time, with statistical significance on all primary and most secondary endpoints.

"This conference provides an excellent venue for CNS Response, as the Forum's goal is to provide exposure for the most promising companies in the healthcare sector," commented Carpenter.

A simultaneous webcast of the CNS Response presentation will be available at [ www.OneMedPlace.com ], where it will be archived after January 12, 2010.

About CNS Response

Today, most physicians are able to base treatment on objective test data, such as EKGs, MRIs, blood tests, etc. Broadly speaking, such advances have not yet come to those physicians practicing psychiatry.

CNS Response has developed a patented data-analysis capability that, with the help of a simple, non-invasive EEG, will analyze a patient's brain waves and compare the results to an extensive patient outcomes database. The process produces a rEEG® report providing a psychiatrist with guidance to personalize medication regimens for a patient, based on the patient's own brain physiology. To read more about the benefits this patented technology provides physicians, patients and insurers, please visit [ www.cnsresponse.com ].

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.